Top Industry Leaders in the Hemoglobinopathies Market
Latest Hemoglobinopathies Companies Update
April 2023: ECHO India, a non-profit organization dedicated to building India's healthcare capacity, has partnered with the Post Graduate Institute of Child Health (PGICH) to create a statewide initiative focusing on the prevention and control of beta thalassemia and other hemoglobinopathies. The program, which began today with a rigorous two-day Training of Trainers (ToT), will be conducted as part of a countrywide collaborative project. The National Hub for ECHO India's initiative will be PGICH, a prominent paediatric facility created. This effort intends to train healthcare personnel across the country in the prevention and management of Beta Thalassemia and other Hemoglobinopathies, with a focus on distant and disadvantaged areas.
February 2023: Vertex Therapeutics celebrated the launch of the first CRISPR-based gene editing medication as it nears completion of a historic FDA filing. Vertex estimates that a network of around 50 authorized treatment sites in the United States and 25 in Europe will be sufficient for its exagamglogene autotemcel, or exa-cel, gene therapy candidate for sickle cell disease and beta thalassemia. These individuals require many hospitalizations per year for vaso-occlusive crises or are dependent on blood transfusions on a regular basis. In November 2022, Vertex and CRISPR Therapeutics began submitting exa-cel for sickle cell disease and beta thalassemia. Outside of the United States, regulatory process has been a little speedier, since the European Medicines Agency and authorities in the United Kingdom have already confirmed the files.List of Hemoglobinopathies Key companies in the market
- Sanofi
- Sangamo Therapeutics, Inc.
- Global Blood Therapeutics
- Neusoft Medical Systems Co., Ltd
- Bluebird Bio, Inc.
- Emmaus Life Sciences Inc.
- Prolong Pharmaceuticals
- Celgene Corporation
- Alnylam Pharmaceuticals
- Gamida Cell
- Acceleron Pharma
- Mast Therapeutic
- HemaQuest Pharmaceuticals